JAK2 and myeloid neoplasm: Hence, this work reveals what we believe to be new signaling dynamics that enhance our understanding of compartmentalized RAS signaling, suggesting RAB27B as a therapeutic target to abrogate oncogenic CBL/JAK2 and RAS-driven myeloid malignancies.